ClinicalTrials.gg
Enrolling by invitationNCT07326657LOGIUpdated Nov 12, 2026

Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns

A Phase 4 interventional study of Intact fish skin graft and autograft in Partial-thickness Burn Wounds, sponsored by Kerecis Ltd.. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Kerecis Ltd. (part of Coloplast A/S) · Phase 4, Interventional, and Treatment

How we know

Updated Nov 12, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Planned enrollment
54th of 272
65 · median 26
Started
2026
with 14 others
Phase 4
25 of 336
6 open now
Primary completion
2029-01
later than 45 of 50 live
Registered
321st of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 54th largest by planned enrollment of the 272 interventional ones that give a count, is one of 15 that started in 2026, is one of 25 in phase 4, reaches primary completion later than 45 of the 50 other live ones, and was the 321st registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

The goal of this randomized controlled clinical trial is to determine whether use of Kericis Intact Fish Skin Graft (IFSG) can decrease the amount of autograft tissue needed for treatment of deep partial-thickness burns in patients at least 18 years of age with a deep partial-thickness burn for whom autograft treatment is clinically indicated. This clinical trial seeks to collect the following:

  1. Difference in the percentage area of the IFSG treatment site and control autograft treatment site that required autografting within 1 month of treatment
  2. Proportion of subjects achieving durable wound closure of the IFSG treatment site without autograft placement within 2 months of treatment
  3. Difference in cosmesis between the IFSG treatment site and autograft treatment site a year after treatment
  4. Difference in the pain intensity between the IFSG treatment site and autograft treatment site

Each participant will receive autograft and intact fish skin graft (IFSG) on different areas of their deep partial-thickness burn. Participants will be assessed for the need for further autograft treatment. Participants will also be assessed for wound closure, pain, and cosmesis.

03

Conditions studied

  • Partial-thickness Burn Wounds

Browse trials for

Keywords

  • burn
  • deep partial-thickness
  • Kerecis
  • fish skin graft
  • autograft
  • split thickness skin graft
  • fish skin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age at time of consent
  2. Must have thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated.
  3. Be able to provide written or have a legally authorized representative
  4. Have sufficient healthy skin identified and designated as a potential donor site in the event that the IFSG treatment site requires autografting.
  5. Investigator expects that the donor site will heal without grafting
  6. Have a complex skin defect of 3 to 49% Total Body Surface Area, which can consist of more than one contiguous area

    At the time of debridement:

  7. Have thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated
  8. Study treatment areas can be up to 2000 cm2
  9. Must have at least 100 cm2 TBSA for which autografting is indicated and on which IFSG can be applied, which may be composed of up to 3 non-contiguous areas located on the same extremity or plane of the torso
  10. Application of IFSG or SOC must be initiated within 14 days of injury (Application of IFSG or SOC must be initiated within 14 days of injury)
  11. Have first excision and grafting of study treatment sites
  12. Have thermal burn(s) on the torso or extremities

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to fish (shellfish allergy is OK)
  2. Female who is actively pregnant or currently breast-feeding
  3. Vulnerable populations
  4. Currently receiving systemic therapy
  5. Current or known history of or receipt of chemotherapy
  6. History of Diabetes with documented uncontrolled diabetes (as defined by an >9) within the last 6 months
  7. Have an expected survival of less than 3 months
  8. Are currently participating/have participated in the treatment group of an interventional study within 90 calendar days prior to consent
  9. Have other wounds present for > 30 days

    At the time of debridement:

  10. Treatment area is assessed as full-thickness after debridement
  11. Treatment areas on the face, neck, head, hands, feet, buttocks, perineum, and areas over joints (Treatment areas may only be on the torso or extremities)
  12. Have a clinical or laboratory determination of infection at the anticipated treatment sites.

    -

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    IFSG-Treated Area of Burn

    The area of the deep partial-thickness burn that is treated with IFSG

    Device: Intact fish skin graft

  • Active comparator
    SOC Autograft-Treated Area of Burn

    The area of the deep partial-thickness burn that is treated with autograft as standard-of-care

    Procedure: autograft

Interventions

  • DeviceIntact fish skin graft

    Treatment with IFSG

  • Procedureautograft

    Treatment with autograft

06

What researchers measure

Primary outcomes

  1. Difference in percentage area of the IFSG treatment site and control autograft treatment site that required autografting by 1 month.

    Time frame: From initial surgical IFSG/autograft treatment post-enrollment to 28 +/- 3 days later

Secondary outcomes

  1. Proportion of subjects achieving durable wound closure of the intact fish skin treatment site at Month 2 without autograft placement

    Time frame: From initial treatment with IFSG/autograft post-enrollment to 60 +/- 7 days later

  2. Difference in cosmesis between the IFSG treatment site and autograft treatment site at Month 12 based on observer POSAS total score

    Scar quality will be assessed using the Patient and Observer Scar Assessment Scale (POSAS) that describes scar quality on a scale from 1-10 with 1 being a scar very similar to normal skin and 10 being a severe scar very unlike normal skin.

    Time frame: From initial treatment with IFSG/autograft post-enrollment to 365 +/- 30 days later

  3. Difference in the pain intensity between the IFSG treatment site and autograft treatment site one week after treatment based on the Wong-Baker FACES pain rating scale (FPRS)

    The Wong-Baker FACES pain rating scale presents a range of faces with a happy face associated with a score of 0, meaning "no hurt", to a very sad face associated with a score of 10, meaning "hurts worst."

    Time frame: From initial treatment with IFSG/autograft post-enrollment to 7 +/- 1 days later

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2029, 31 months after the start.

Of 21 phase 4 interventional studies under Burns, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 43. This study's planned 31 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jun 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jan 8, 2026
StartActual
Jun 1, 2026was Jan 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 2026→Jun 1, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Jan 2026→Jun 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07326657
Lead sponsor
Kerecis Ltd.
Collaborators
American Burn Association, BData, Inc.
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Jun 1, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion